ArticleCurrent oncology (Toronto, Ont.)2016
Hepcidin and ferroportin expression in breast cancer tissue and serum and their relationship with anemia.
Article in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Serum Hepcidin Levels in Breast Cancer Patients: Investigating the Correlation to Tumor Stage-A Cross-Sectional Study.Health science reports · 2025Article
- Iron-Deficiency Anemia Associated With Prostate Cancer, and Ameliorated by Anti-androgen Therapy.Cureus · 2025Article
- The Impact of Iron on Cancer-Related Immune Functions in Oncology: Molecular Mechanisms and Clinical Evidence.Cancers · 2024Review
- Review
- Therapy-induced senescence in breast cancer: an overview.Exploration of targeted anti-tumor therapy · 2024Review
- HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.British journal of cancer · 2023Review
- Review
- Hepcidin and erythroferrone response to 3 weeks of exposure to normobaric hypoxia at rest in trained cyclists.Frontiers in physiology · 2023Article
- Therapy-resistant nature of cancer stem cells in view of iron metabolism.Inflammation and regeneration · 2022Review
- Article
- Iron-Bound Lipocalin-2 from Tumor-Associated Macrophages Drives Breast Cancer Progression Independent of Ferroportin.Metabolites · 2021Article
- Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment.Oxidative medicine and cellular longevity · 2021Review
- Hepcidin Upregulation in Lung Cancer: A Potential Therapeutic Target Associated With Immune Infiltration.Frontiers in immunology · 2021Article
- The Role of Iron in Cancer Progression.Frontiers in oncology · 2021Review
- The effect of red blood cell transfusion on plasma hepcidin and growth differentiation factor 15 in gastric cancer patients: a prospective study.Annals of translational medicine · 2019Article
- Ferroportin-Hepcidin Axis in Prepubertal Obese Children with Sufficient Daily Iron Intake.International journal of environmental research and public health · 2018Article
- Increased expression of hepcidin and associated upregulation of JAK/STAT3 signaling in human gastric cancer.Oncology letters · 2018Article
- Expression of Hepcidin and Neogenin in Colorectal Cancer.Open medicine (Warsaw, Poland) · 2017Article
- Nuclear transcription factor Nrf2 suppresses prostate cancer cells growth and migration through upregulating ferroportin.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur correlation study investigated the relationships of the expression of hepcidin and ferroportin (fpn) in tissues and serum from breast cancer (bca) patients and the relationships of hepcidin and fpn with anemia.
methodsWe used elisa and immunohistochemistry to detect the expression of hepcidin and fpn in tissue and serum from 62 individuals with bca, and we analyzed correlations between hepcidin and fpn expression in tissue and in serum. At the same time, we evaluated the relationships between hepcidin, fpn, and anemia.
resultsMean serum hepcidin was 8.18 ± 3.75 μg/L in bca patients with anemia and 4.53 ± 2.07μg/L in those without anemia, a statistically significant difference (t = 3.7090, p < 0.01). Mean serum fpn was obviously lower in the anemia group than in the non-anemia group (1.77 ± 0.51 μg/L vs. 2.46 ± 0.52 μg/L, t = 3.5115, p < 0.01). Serum hepcidin and hemoglobin were negatively correlated (r = -0.502, p < 0.01); however, serum fpn was positively correlated with hemoglobin, and serum hepcidin was negatively correlated with fpn. The rates of hepcidin and fpn expression in bca tissues were 50.0% and 61.2% respectively, but no association with anemia was observed. We also observed no relationship between expression of hepcidin and fpn in serum and in tissue.
conclusionsIn bca patients, expression of hepcidin in serum was high, but expression of fpn was low, suggesting that serum hepcidin plays a major role in anemia in those patients. Expression of hepcidin and fpn in bca tissue showed no correlation with their expression in serum and no clear relationship with anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.